PMID- 34708280
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 100
IP  - 12
DP  - 2021 Dec
TI  - The optimal timing of radiotherapy in the combination treatment of limited-stage 
      extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis.
PG  - 2889-2900
LID - 10.1007/s00277-021-04700-y [doi]
AB  - This study was designed to explore the relative efficacy and toxicity of upfront 
      radiotherapy (RT) and late RT in combination treatments for patients with 
      limited-stage extranodal natural killer/T-cell lymphoma nasal type (LS-ENKTL). We 
      searched for clinical trials in the PubMed database that compared upfront RT with 
      late RT in the combined treatment of patients with LS-ENKTL. We systematically 
      evaluated the differences in survival, treatment response, and treatment-related 
      adverse events (AEs) between these two groups. Ten retrospective studies with a 
      total of 1752 patients were included. Upfront RT significantly prolonged the 
      overall survival (OS) and progression-free survival (PFS) of patients compared to 
      late RT in combination with chemotherapy (CT) (HR = 0.72, 95% CI 0.59-0.88, 
      P = 0.001 for OS; HR = 0.57, 95% CI 0.41-0.79, P = 0.0007 for PFS). The complete 
      remission (CR) rate in the upfront RT group was superior to that in the late RT 
      group (HR = 1.61, 95% CI 1.09-2.37, P = 0.02). Patients experienced similar local 
      recurrence-free survival (LRFS), objective response rates (ORR), and toxicity 
      between these two arms (P > 0.05 for all) in the analysis of each subgroup. The 
      survival benefit of upfront RT was not correlated with the RT dose, concurrent 
      chemoradiotherapy (CCRT) (or not), or the CT regimen (P > 0.05 for all). Without 
      compromises in terms of toxicity, RT dose, and treatment modality, upfront RT can 
      significantly benefit OS, PFS, and CR compared to late RT in combination 
      treatment. These findings verified that the upfront RT regimen is more suitable 
      for patients with LS-ENKTL.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Cui, Yue
AU  - Cui Y
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Yao, Yuyi
AU  - Yao Y
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in Southern 
      China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, 510060, China.
FAU - Chen, Meiting
AU  - Chen M
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in Southern 
      China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, 510060, China.
FAU - Jiang, Yongsheng
AU  - Jiang Y
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430030, China. 
      ysjiang.china@163.com.
FAU - Ren, Quanguang
AU  - Ren Q
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430030, China. renqg88@sina.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211027
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Chemoradiotherapy/adverse effects/methods
MH  - Combined Modality Therapy/adverse effects/methods
MH  - Humans
MH  - Lymphoma, Extranodal NK-T-Cell/*radiotherapy/therapy
MH  - Radiation Dosage
MH  - Radiotherapy/adverse effects/methods
MH  - Survival Analysis
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Concurrent chemoradiotherapy
OT  - Extranodal NK/T-cell lymphoma
OT  - Sandwich therapy
OT  - Sequential chemoradiotherapy
OT  - Upfront radiotherapy
EDAT- 2021/10/29 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/10/28 06:47
PHST- 2021/08/03 00:00 [received]
PHST- 2021/10/10 00:00 [accepted]
PHST- 2021/10/29 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/10/28 06:47 [entrez]
AID - 10.1007/s00277-021-04700-y [pii]
AID - 10.1007/s00277-021-04700-y [doi]
PST - ppublish
SO  - Ann Hematol. 2021 Dec;100(12):2889-2900. doi: 10.1007/s00277-021-04700-y. Epub 
      2021 Oct 27.